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In oncology, prognostic markers are clinical measures used to help elicit an individual patient’s risk of a future outcome, such as
recurrence of disease after primary treatment. They thus facilitate individual treatment choice and aid in patient counselling. Evidence-
based results regarding prognostic markers are therefore very important to both clinicians and their patients. However, there is
increasing awareness that prognostic marker studies have been neglected in the drive to improve medical research. Large protocol-
driven, prospective studies are the ideal, with appropriate statistical analysis and clear, unbiased reporting of the methods used and
the results obtained. Unfortunately, published prognostic studies rarely meet such standards, and systematic reviews and meta-
analyses are often only able to draw attention to the paucity of good-quality evidence. We discuss how better-quality prognostic
marker evidence can evolve over time from initial exploratory studies, to large protocol-driven primary studies, and then to meta-
analysis or even beyond, to large prospectively planned pooled analyses and to the initiation of tumour banks. We highlight articles
that facilitate each stage of this process, and that promote current guidelines aimed at improving the design, analysis, and reporting of
prognostic marker research. We also outline why collaborative, multi-centre, and multi-disciplinary teams should be an essential part
of future studies.
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In oncology, prognostic markers (also called prognostic factors)
are clinical measures used to help elicit an individual patient’s risk
of a future outcome, such as recurrence of disease after primary
treatment. They play a key role in clinical practice, distinguishing
patients into different risk groups and thus informing treatment
strategies and aiding patient counselling. They can also be used to
define strata in clinical trials to ensure comparability of treatment
groups. Markers can be simple measures, such as the stage of
disease or tumour size, but are often more complex, such as
abnormal levels of proteins or genetic mutations. For example,
within paediatric oncology, amplification of the MYCN proto-
oncogene is a known indicator of poor outcome in neuroblastoma
patients (Riley et al, 2004a). In adult oncology, it is well known
that the number of positive lymph nodes has a strong influence on
the prognosis of recurrence-free survival time in patients with
primary breast cancer (Galea et al, 1992). For (nearly) all diseases,
some important prognostic markers have been well established for
a long time, but many more are investigated each year. Few,
however, find a role in clinical practice.
Not all potential markers turn out to have prognostic value.
Much research effort goes into conducting studies that evaluate the
extent to which certain markers help clinical prognosis. Indeed,
hundreds of prognostic marker studies are published in cancer
journals each year. Unfortunately, though, there is large concern
about the quality of such studies and it is clear that large progress
is needed to produce clinically relevant results (Hinestrosa et al,
2007). Over more than 10 years, an increasing body of evidence has
signalled that prognostic marker studies are often badly designed
(Simon and Altman, 1994; Altman and Lyman, 1998), inappropri-
ately analysed (Holla ¨nder and Sauerbrei, 2006), poorly reported
(Riley et al, 2003; Kyzas et al, 2005), and subject to numerous
biases, such as selective reporting (Kyzas et al, 2005, 2007a) and
‘optimal’ choice of cutpoints (Altman et al, 1994). Bad quality
of design, analysis, and reporting of individual studies result
in confusion regarding the prognostic value of a new marker
(Sauerbrei, 2005). Furthermore, evidence-based marker results are
a rarity, with systematic reviews and meta-analyses of multiple
studies serving only to highlight the serious deficiencies within
primary prognostic research (Altman, 2001). For example, two
systematic reviews, one in neuroblastoma (Riley et al, 2004a) and
another in non-small-cell-lung cancer (Brundage et al, 2002),
found that over 100 different prognostic markers have been
investigated in each field, yet the median number of articles per
marker was only 1. Clinicians are thus faced with a confusing yet
ever-growing body of literature, where new markers are regularly
investigated but rarely in relation to existing markers. The
evidence-base is further blurred by large heterogeneity across
studies in the patient population, the method of measuring each
marker, the outcomes reported, and the statistical analyses used,
among numerous other factors (Riley et al, 2003), all of which limit
a coherent meta-analysis.
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www.bjcancer.comIn this paper, we examine the key methodological issues of the
prognostic marker research process, encouraging a move towards
higher standards and clinically useful results. Our aim is to discuss
how high-quality evidence can evolve over time from initial
exploratory studies, to large protocol-driven primary studies, to
meta-analysis and even beyond, to large prospectively planned
pooled analyses, and to the initiation of tissue banks. The work
extends earlier articles aimed at a more statistical audience
(Altman et al, 2006; Holla ¨nder and Sauerbrei, 2006; Sauerbrei
et al, 2006; Riley et al, 2006a), and focuses on prognostic, rather
than predictive, markers. In cancer, a prognostic marker is one
that predicts a patient’s clinical course, whereas a predictive
marker is one associated with differential responses to a specific
treatment (although this terminological distinction is perhaps not
widespread across medicine). Predictive marker studies are
relatively uncommon, and best embedded within randomised
controlled trials. Sargent et al (2005) discuss how to conduct a
clinical trial that assesses the utility of a predictive marker.
Our paper focuses on studies (or meta-analyses) that seek to
evaluate a small number of pre-specified markers. In recent years,
clinicians have become increasingly enthusiastic about the
possibility of improving prognosis and prediction by applying
the new technologies of measuring many thousands of genes.
However, these technologies create a very large number of
potential predictors and require statistical methods to extract a
relatively small number of relevant items. We also do not consider
the study of prognostic markers from high-dimensional data, such
as microarray studies (Tinker et al, 2006; Dupuy and Simon, 2007).
The outline of the paper is as follows. In the section ‘Primary
studies of progostic markers’, we consider primary studies of
prognostic markers and consider their design, analysis, and
reporting. In the section ‘Systematic reviews and meta-analysis’,
we discuss systematic reviews of such studies and explain why
meta-analyses that use individual patient data (IPD) are important.
In the section ‘Towards multi-centre and collaborative research’,
we consider why prospectively planned pooled analyses and the
initiation of tumour banks may best facilitate evidence-based
prognostic marker results. Finally, in the Discussion section, we
summarise the key messages for future research.
PRIMARY STUDIES OF PROGNOSTIC MARKERS
Study design
In the initiation of prognostic marker studies, as Altman and
Lyman (1998) suggest, every effort must be made to limit potential
biases and emulate the design standards expected of a protocol-
driven randomised trial. Researchers should begin with a clear and
well-defined research question so that their study can be designed
and targeted appropriately. Unfortunately, it seems that many
prognostic studies are not motivated by prior questions or by
hypotheses, and few are protocol-driven – ‘investigators may tend
to conduct opportunistic studies on the basis of specimen avail-
ability rather than on thoughtful design’ (Kyzas et al, 2007b). For
example, often no justification is made for the sample size used, or
whether the markers, sub-populations, and outcomes assessed
were determined before beginning the study. It can be speculated
that the main motivation for a quick analysis of some pre-existing
data is another publication rather than scientific importance. It is,
however, good practice for all research to have a study protocol
outlining the aims and detailing the methods that will be used.
Prognostic marker studies have several possible aims, including
the desire to understand more about the biology of a disease
process. However, the vast majority of studies aim to investigate
the association between one or more markers with an outcome (or
multiple outcomes) of interest. In cancer, these outcomes are
usually death, recurrence of disease, or both. For such studies,
three different study phases have been proposed (Figure 1), which
are similar in spirit to those proposed for biomarker development
(Pepe et al, 2001; Ransohoff, 2007), and prognostic factor studies
in general (Hayden et al, 2008). They begin with exploratory
studies to identify promising prognostic markers and move
towards larger, preferably prospective, confirmatory studies. Phase
I studies are early exploratory analyses to generate hypotheses and
to identify potential markers for further investigation. Phase II
studies continue the exploratory investigation and assess the
relationship between marker and prognosis. Phase III studies are
large, confirmatory studies that state prior hypotheses, potentially
based on earlier phase II results. These studies should certainly be
protocol-driven and must be seen as the highest level of evidence
that can arise from an individual prognostic study.
It is important for researchers to consider a priori which of these
study types fit their research objective. There is nothing wrong
with exploratory and hypothesis generating phase I or II studies.
Furthermore, additional exploratory analyses of phase III studies
are encouraged, as all such exploratory works help to identify
potentially important markers and to validate measurement
techniques. However, it is important that this type of research is
clearly labelled and interpreted as such. After the publication of
several small phase I or II studies, it seems useless, or even
harmful, to proceed with further such studies for a particular
marker of interest (Schmitz-Dra ¨ger et al, 2000). Research efforts
should rather concentrate on larger collaborative phase III
projects. The availability of a study register would help researchers
to decide about starting further smaller studies or whether the time
has come for a collaborative phase III study. Study registers would
also prevent duplication of research effort, and allow transparency
of all the markers that have been investigated, not just those found
to be potentially important. Study registers are an integral part of
randomised trials (Horton and Smith, 1999), thanks to many years
of petitioning (Simes, 1986), and this sets the standard for
transparent prognostic marker studies to follow. We note that such
registers may be easier to achieve for phase III prognostic studies,
which are pre-planned and protocol-driven by nature. On the
contrary, a concern is that, owing to their opportunistic nature,
many phase I or II studies would only be registered if they identify
a significant finding, resulting in a biased set of registered phase I
and II studies, akin to the problem of publication bias. Registration
before the start of a study would be ideal, but we are aware that it
1. Phase I: Exploratory studies (hypothesis generating) that seek an association 
between a prognostic marker and characteristics of disease thought to have 
prognostic importance. 
2. Phase II: Exploratory studies attempting to use values of a prognostic marker to 
discriminate between patients at high and low risk of disease progression or death.
3. Phase III: Confirmatory studies of a priori hypotheses attempting to use values of a 
prognostic marker to discriminate between patients at high and low risk of disease 
progression or death.
Figure 1 Types of prognostic marker studies, modified from Altman and Lyman (1998).
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studies.
Unfortunately, the current literature indicates that phase I and II
studies are by far the most common, with the higher-quality phase
III studies unfortunately quite rare. This is disappointing, as
results from phase III studies are more reliable and should
underpin which markers are implemented in practice. Simon and
Altman (1994) presented requirements of a prognostic marker for
acceptance in clinical practice (Figure 2), and these include
confirmation from phase III studies that the marker has inde-
pendent prognostic ability beyond other markers used in practice
(Kattan, 2003). Factors to consider in the design of phase III
studies are shown in Figure 3. An ideal approach would involve
following a well-defined cohort of patients from the same stage
of their disease. Such a sample is often an ‘inception’ cohort of
patients at the time of diagnosis of cancer. The use of study
protocols, pre-specified study objectives, and prior hypotheses are
essential. Detailed consideration should be given to the sample
selection, inclusion and exclusion criteria, treatment (if possible
randomised or standardised), the use of standardised assays, and
statistical analysis (see later). For phase III studies, sample size
should be large enough to sustain meaningful analysis, preferably
with hundreds of events, and to ensure that the marker of interest
can be assessed alongside existing markers of prognostic impor-
tance. Kyzas et al (2007b) highlight that power calculations for the
required sample size are rarely presented in published prognostic
marker studies. Procedures are also needed to ensure missing data
are minimised and completeness of follow-up is maximised.
Although protocol-driven prospective studies are the ideal (Van
Meerbeeck, 1994; Altman and Lyman, 1998), unfortunately the
large majority of prognostic studies in cancer are retrospective
and, it seems, not protocol-driven. A review of 331 prognostic
marker studies identified only 20% that were prospective (Kyzas
et al, 2007b), in the sense that the data were collected after the
research question was posed. The big advantage of retrospective
studies is the availability of a cohort with a long enough follow-up
to assess a substantial number of outcome events (deaths or
recurrences). Retrospective studies, however, have several serious
disadvantages. Foremost among these are problems associated
with the lack of a fully specified design for the study: unclear
inclusion criteria, unknown completeness of the cohort, lack of
standardisation of diagnostic and therapeutic procedures, incom-
plete baseline data, and unclear completeness of follow-up. A move
towards prospective prognostic studies is thus encouraged,
especially within phase III research. This may require collabora-
tion among multiple research groups, so to achieve larger sample
sizes and consistency across groups in important factors (e.g.,
measurement techniques, cutpoints used). Such studies can best be
integrated in large therapeutic trials, but a protocol-based pre-
planned pooled analysis of retrospective data from several centres
is also possible (see the section ‘Towards multi-centre and
collaborative research’).
Statistical analysis
For therapeutic studies, statistical principles and methods are well
developed and generally accepted. In contrast, no such consensus
exists for the evaluation of prognostic markers. Holla ¨nder and
Sauerbrei (2006) showed that the choice of statistical method has a
strong influence on the results and, therefore, on the interpretation
of prognostic marker studies. Focusing on prognostic markers in
oncology, they discuss issues of statistical model building in the
framework of regression models and of classification and
regression trees. Other approaches, for example, artificial neural
• Determination is reproducible and widely available with quality control.
• Substantial added value beyond recognised prognostic systems is shown.
• Conclusions are based on independent confirmed phase III studies.
Figure 2 Requirements of a prognostic marker for acceptance in clinical
practice, modified from Simon and Altman (1994).
• The primary and secondary hypotheses should be clearly stated, including any 
subgroup analyses in advance of the study.
• Consider prognostic markers for which there is sufficient evidence to warrant 
further investigation based on:  
(a) previous studies;
(b) biological and clinical plausibility;
(c) relevance and importance to the understanding or treatment of the disease.
• The study population should be defined with specified inclusion and exclusion 
criteria and methods to judge evaluability.
• Patient treatment should if possible be either  rule-based (several treatment strategies
are allowed) or assigned by randomisation. 
• Assays should be reproducible and should be performed without knowledge of the 
clinical data and patient outcome. Preferable to use a standardised assay that is 
commonly used and available. 
• Estimate the sample size keeping in mind the following: 
(a) the desired power to detect meaningful difference for the major end points 
and to reject such differences with reasonable confidence if they are not 
found;
(b) the relationship of sample size to the  number of outcome events, bearing in 
mind that these will be less frequent in favourable prognostic groups;
(c) the desirability of large prospective studies of a single prognostic marker.
• Outline how missing data will be minimised, and completeness of patient follow-up 
maximised.  
• Specify the statistical analysis plan (SAP) including details on cutpoints or the 
modelling of functional relationship for continuous variables, proposed hypothesis 
testing on subgroups, anticipated interactions in advance of the study, and how 
missing data will be handled.
• Key study features, including the above information, should be fully detailed in a 
formal written protocol.
Figure 3 Factors to consider in the design of a high-quality phase III study, modified from Altman and Lyman (1998).
Prognostic markers in cancer: the evolution of evidence
RD Riley et al
1221
British Journal of Cancer (2009) 100(8), 1219–1229 & 2009 Cancer Research UKnetworks, are sometimes used for the analysis of marker studies
but have several drawbacks (for more detailed discussion on
this topic see Schwarzer et al, 2000; Schumacher et al, 2006).
Parametric survival models are also possible, but are rarely used
for the identification of prognostic markers.
For the analysis of a prognostic marker study, we consider
multivariable regression models as the method of choice, such as
the Cox model, which is often suitable for survival-type data that
arises from prognostic studies. This assessment is based on both
personal experiences and the results of simulation studies
considering a restricted range of model-building issues (Sauerbrei,
1999; Royston and Sauerbrei, 2008). Multivariate analyses are easy
to perform and provide prognostic marker results adjusted for
other markers; this is imperative to assess the added value of a new
marker over existing markers (Kattan, 2003), which should be the
standard practice but is currently the exception in the prognostic
marker literature (Kyzas et al, 2005).
Within regression models, a central issue is whether to use the
full model incorporating all available variables or a reduced model
determined by variable selection methods. Although it is well
known that variable selection has several difficulties (Sauerbrei,
1999; Harrell, 2001), these strategies are often required to derive a
sensible, interpretable, and parsimonious model (Sauerbrei, 1999;
Royston and Sauerbrei, 2008). A more crucial issue is the way in
which continuous markers are analysed. We believe it is central to
make maximal use of the data and determine a sensible functional
form (Royston et al, 2006; Sauerbrei et al, 2007; Royston and
Sauerbrei, 2008). Researchers may retain a variable as a continuous
measurement but they often assume a linear relation to outcome,
which is unwise. More often they choose to avoid such issues by
dichotomising, often at the sample median. This popular ‘step
function’ approach contradicts biological thinking and has major
methodological deficiencies, not least the reduced statistical power
(Royston et al, 2006). Using the so-called ‘optimal cutpoint’
approach is the worst form of the step function approach, as it
introduces considerable bias (Altman et al, 1994; Royston et al,
2006). Use of more than one cutpoint is better than having just
one, but we believe that full use of the available data mandates a
careful analysis that uses the actual continuous marker values
(Holla ¨nder and Sauerbrei, 2006; Royston and Sauerbrei, 2008).
Recommendations towards model building by the selection of
variables and functional forms for continuous markers are
available (Sauerbrei et al, 2007).
An important statistical topic that is often neglected in prognostic
marker studies is model validation with external data (Holla ¨nder
and Sauerbrei, 2006). Schumacher et al (2006) state that: ‘A
multivariate approach is absolutely essential. Thoughtful application
of model building techniques should help to obtain models that are
as simple and parsimonious as possible and to avoid serious
overfitting in order to achieve generalisability for future patients.
Thus, validation in an independent study is a further essential step’.
Unfortunately, most markers or combination of markers used as the
basis for classification schemes never undergo external validation in
a new data, and those that do rarely maintain their prognostic
ability (Sauerbrei et al, 1997); consequently, many so-called
prognostic markers are often not accepted for general use (Wyatt
and Altman, 1995; Boracchi and Biganzoli, 2003). Altman and
Royston (2000) propose that statistical and clinical validation of
prognostic models is required, and they examine some general
approaches to do this. One way of validating whether a marker truly
is prognostic is to look at the results across multiple studies (meta-
analysis), but this may be difficult without IPD (see section ‘The
benefit of IPD’) (Tudur-Smith et al, 2005). Bennett (2003) provides a
helpful review of analytic methods for analysing time-to-event data
in single studies and meta-analysis, considering non-standard issues
such as non-proportional hazards and heterogeneity.
Kattan (2003), and also Katz and Kattan (2005), highlights that
the added value of new prognostic markers should be assessed not
only by multivariate analyses but also through their ability to
improve predictive accuracy. Two new measures applicable to
models for binary outcome are proposed by Pencina et al (2008).
Pepe et al (2004) also state that: ‘Markers proposed for classifying
or predicting risk in individual subjects must be held to a much
higher standard than merely being associated with outcome.’
Vickers and Elkin (2006) provide a novel method for evaluating
prediction models, whereas Henderson and Keiding (2005) argue
that although prediction models can be useful at the group or the
population level, they are usually of no real use for individual
patients because of the large uncertainty in human survival.
In Figure 4, we reproduce the important issues for the analysis
of a prognostic marker study from Holla ¨nder and Sauerbrei (2006).
As for all high-quality, protocol-driven research, we recommend
that the statistical analysis plan of a prognostic marker study
should be specified in the study protocol and include details of
how the independent prognostic importance of the marker will be
ascertained in relation to existing markers of clinical importance.
Furthermore, such pre-specified analyses should be complemented
by sensitivity analyses of central assumptions and by additional
model building using suitable strategies. These latter results are
explanatory, which should be clarified in the study report.
Study reporting
In addition to improving the design and analysis of primary
studies, there is also a pressing need to improve their reporting
standards, as serious deficiencies have been exposed (Altman et al,
1995; Riley et al, 2003; Burton and Altman, 2004; Kyzas et al, 2005,
2007a). Published studies currently lack sufficient information to
allow a full appreciation of the methodological quality of the study,
the methods, and analyses undertaken, or the applicability of the
study results for practice. For instance, the following rudimentary
factors are often not reported: the number of patients in each
marker group; the number of events in each group; the method of
measuring each marker; the cutpoint used to dichotomise a
continuous marker into ‘high’ and ‘low’ levels; a measure of effect,
such as a hazard ratio, and its confidence interval; marker results
adjusted for other clinically useful markers; and which analyses,
outcome, and markers were primary (pre-defined) objectives and
which were exploratory secondary assessments (Riley et al, 2003).
Kyzas et al (2007b) reviewed 331 cancer prognostic studies from 20
meta-analyses, and concluded that the reporting quality of study
design and assay information was often suboptimal. Such gaps in
reporting may explain why most systematic reviews of prognostic
markers do not include an adequate quality appraisal of the studies
identified (Hayden et al, 2006).
There is also evidence that prognostic results are often subject to
selective reporting, meaning that some of the markers, outcomes,
and analyses considered are not reported upon publication (Kyzas
et al, 2005). This issue is associated with the common threat of
publication bias (Sterne et al, 2001; Rothstein et al, 2005), where
studies that do not identify statistically or clinically significant
results are not published. Such publication bias is well recognised
for randomised trials, even for Food and Drug Administration
(FDA)-registered studies (Turner et al, 2008), and it seems certain
that this bias also affects prognostic studies to a great extent. The
biggest example so far was shown by Kyzas et al (2007a), who
found that o1.5% of 1915 articles on cancer prognostic markers
were fully ‘negative,’ in that they did not present statistically
significant prognostic results and did not, for example, elaborate
on nonsignificant trends. Selective publication is likely to lead to
larger effects that are seen in smaller studies (Sterne et al, 2001;
Rothstein et al, 2005). For example, in a systematic review of
studies of Bcl2 in non-small-cell lung cancer, almost all the smaller
studies showed a statistically significant relationship between Bcl2
and the risk of dying, whereas the three large studies were all
nonsignificant and showed a much smaller effect (Martin et al,
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probably cluttered with false-positive studies that would not have
been submitted or published if the results had come out
differently’. Such publication bias would thus lead to the literature
being biased towards over-estimating the prognostic importance of
markers.
Rifai et al (2008) believe that it is time to take action against
reporting biases in prognostic studies. To encourage clear and
transparent reporting of prognostic marker studies, some recent
articles have provided reporting guidelines. The REMARK guide-
lines (McShane et al, 2005b) consider the whole study process and
suggest the key information that needs reporting, from the pre-
defined hypotheses and patients included, to the statistical analysis
methods used and the results identified, and to the study
limitations and implications for clinical practice. Journal editors
are encouraged to enforce adherence to these guidelines before
accepting a prognostic marker article. In addition, Burton and
Altman (2004) consider how to report prognostic studies when
there are missing covariate data, whereas Riley et al (2003) suggest
how effect estimates and summary results should be reported
(Figure 5), with a recommendation to also provide IPD to facilitate
meta-analysis.
SYSTEMATIC REVIEWS AND META-ANALYSIS
Current difficulties for evidence synthesis
An evidence-based approach to prognostic markers is clearly
needed. It is usually difficult to ascertain the benefit of a marker
from a single published study, which may be overoptimistic owing
to small sample size and selective reporting, and a clear view is
only likely to emerge from looking across multiple studies.
However, clinicians do not have the time to review such a plethora
of marker studies, and ideally need the most suitable prognostic
markers to be identified for them, as exemplified by the American
Society of Clinical Oncology in breast cancer (Harris et al, 2007).
To aid this process, a systematic review is commonly used, which
is an approach for identifying, evaluating and summarising
an evidence-base. The term ‘systematic’ comes from the fact that
the review process is performed using systematic and explicit
methods, so that the review should be transparent and reprodu-
cible. If appropriate, a meta-analysis can be carried out at the end
of a systematic review, which is a statistical approach that suitably
combines the quantitative evidence from all the available studies
(or from the subset of better-quality studies) to produce overall
results for practice (Sutton et al, 2000).
Traditionally, meta-analysis methods use data extracted from
published reports, but even for a summary assessment of a
treatment effect from randomised trials, this approach has severe
limitations (Piedbois and Buyse, 2004). Indeed, systematic reviews
and meta-analyses of published prognostic studies generally
highlight a confusing picture and are usually limited in their
conclusions. As individual studies of prognostic markers are often
poorly designed and poorly reported, the available evidence for
synthesis is seriously limited. Also, multiple studies of a particular
marker typically vary in important ways, such as the assays
used, inclusion criteria for patients, types of treatment, cutpoint
level, clinical outcomes, and statistical analysis. This methodo-
logical variation introduces heterogeneity between studies, and
compounds the problem of summarising a marker’s prognostic
importance and identifying how to implement it in practice. For
1. Treatment of study population:
• ideally patients without any systemic adjuvant therapy, but unrealistic in many diseases;
• standardisation or randomisation of treatment preferable, adjustment for treatment in the  
analysis.
2. Model-building process:
• multivariable model required to assess the effect of a marker;
• many approaches available, no general agreement concerning preferable strategies;
• our preference are regression models, other approaches can give complementary 
information.
2a Regression models:
• problems caused by categorisation of continuous covariates;
• standard assumption of a (log-)linear effect of continuous markers may be wrong;
• variable selection methods sensible to select relevant markers, complexity of the 
“final” regression model depends on nominal significance level;
• different variable selection strategies may result in different “final” regression models
2b Trees:
• uncritical application of trees can lead to large, instable and uninterpretable trees;  
• P-value correction and pre-specification of cutpoints for continuous variables  
2c Other approaches:
• many methods available, not without problems.
3. Formation of risk groups:
• different model building strategies may result in different risk groups;  
• avoid too small risk groups.  
4. Validation of results:
• overestimation of effects caused by data-dependent modelling;
• validation of prognostic relevance of markers and models in independent validation study.  
5. Issues requiring more attention in future studies  
• stability investigation of selected models;
• combining variable selection with shrinkage;
• differentiation  between  studies  developing a prediction  model  from  studies  with    
main interest in one specific marker.
Figure 4 Summary of important issues for the analysis of single prognostic marker studies (Holla ¨nder and Sauerbrei, 2006).
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prostate cancer to establish whether age is a prognostic marker,
but the incomplete and heterogeneous nature of the reports
prohibited any quantitative overview. Other issues that commonly
hinder meta-analysis are the use of assays that are non-standar-
dised or lacking in reproducibility; inappropriate or misleading
statistical analyses; and optimal cutpoints, publication bias, and
within-study selective reporting, all of which mean that the
available published results are unlikely to represent a true picture.
An assessment of the published results for marker MYCN in
neuroblastoma strongly indicated that publication bias was present
(Riley et al, 2004b), and the meta-analysis result obtained was
likely to be an overestimate of the true prognostic effect for this
marker. Furthermore, a recent review of the tumour suppressor
protein, TP53, in head and neck cancer provides compelling
empirical evidence that selective reporting biases are a major
impediment to a meaningful meta-analysis (Kyzas et al, 2005).
These biases have serious implications not only for meta-analysis
but also for interpretation of the cancer prognostic literature as a
whole (McShane et al, 2005a).
It is particularly important for systematic reviews of prognostic
marker studies to appraise the methodological quality of the
studies identified (Hayden et al, 2006). Often the main benefit of a
systematic review of published prognostic studies is to expose the
problems within primary research, and thus highlight the
appropriate direction of future research. For example, Schmitz-
Dra ¨ger et al (2000) reviewed 43 trials that considered p53
immunohistochemistry as a prognostic marker in bladder cancer,
and concluded that: ‘From this analysis it becomes evident that
further retrospective investigations will not contribute to the
solution of the problem and thus are obsolete. There is an obvious
need for standardisation of the assay procedure and the
assessment of the specimens as well as for the initiation of a
prospective multi-centre trial to provide definite answers.’
Individual prognostic studies are usually carried out indepen-
dently and not in the context of facilitating a systematic review or a
meta-analysis, either during the study process or when writing for
publication. New studies should rather build specifically on the
results of previous studies, forming a collective drive towards
answering questions of real clinical importance. In particular,
when a study assesses the potential of a new prognostic marker, it
should do so in relation to those other markers identified earlier as
important and currently used in clinical practice. For instance, the
stage and grade of disease are used as prognostic indicators in
most tumours, and therefore results for new markers need to be
adjusted for these variables. However, in general, such adjusted
results are not always reported and, even when they are, great
inconsistency exists across studies regarding which factors are
used for adjustment (Riley et al, 2003). This and other quality
issues regarding the analysis of primary studies can be circum-
vented if IPD are available rather than only the published results,
as now considered.
Essential to present:
1) The hazard ratio and its confidence interval, or the loge(hazard ratio) and its  
variance. Markers that have a continuous function should be modelled as a 
continuous variable using appropriate methods. If there is a justifiable reason for 
using a cutpoint for a continuous marker it should be specified at the start of the  
study and clearly reported. 
2) The number of patients and number of events in total. For binary markers (and  
continuous markers if a cutpoint is used) also report the numbers within each 
group.
3) Both unadjusted and adjusted results for each marker. For adjusted results, 
clearly state what variables have been adjusted for. Ideally, a consistency in the set 
of adjustment factors used across studies should be sought through collaborative  
groups working toward prospectively planned pooled analyses. Otherwise, (i) 
always present results adjusted for age and stage of disease, and (ii) consider using 
the same set of adjustment factors as in important earlier studies. 
4) Individual patient data in the paper or on the Internet. Alternatively, clearly 
indicate within the paper how to contact the group for IPD. Information about 
available data on markers that were not analysed should be included. Subject to 
any restrictions imposed by data protection laws and guidelines, include the following: 
• exact initial marker level and how marker was measured;
• time of disease recurrence (if appropriate); 
• follow-up time;  
• final disease status;  
• levels of other existing prognostic markers of recognised and accepted 
importance for current clinical practice; 
• patient subgroup information, e.g., age, stage of disease, type of treatment 
received;
• details of inclusion/exclusion criteria would also be beneficial. 
Highly desirable to present: 
5) Exact P-values. Reporting of results as ‘significant’ or ‘not significant’ is 
insufficient. Very small P-values can be given as P< X (e.g., P < 0.0001), but in 
this case the exact X2 statistic is also needed.  
6) Survival curves showing the difference in survival over time between the groups, 
with clear step and censoring points; also the initial numbers in each group, and    
the number of events and remaining numbers at various time points during follow-
up are needed. 
7) % Survival at n years with a confidence interval using Kaplan–Meier or other  
methods that allow for censoring, together with the number of patients at risk at 
that time in each group. 
Figure 5 Guidelines for reporting the results of a prognostic marker study (Riley et al, 2003).
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The availability of IPD from primary prognostic studies offers
many advantages for meta-analysis (Figure 6). For example, IPD
allows the adequate checking of the data and modelling assump-
tions; unpublished results and outcomes to be obtained; an
extended follow-up of patients; standardised analysis of the data
with proper and consistent handling of continuous variables
(Holla ¨nder and Sauerbrei, 2006; Royston et al, 2006); and suitable
validation of the models developed (Altman and Royston, 2000;
Holla ¨nder and Sauerbrei, 2006). It may also increase the
opportunity to evaluate combinations of markers, which may
produce more specific and accurate prognostic assessments than
the individual markers themselves. We thus strongly recommend
the IPD meta-analysis approach, but recognise that IPD may not
solve all the problems (Stewart and Tierney, 2002), such as poorly
designed primary studies. It may also be costly and time-
consuming to obtain, or only available from a proportion of
studies (Riley et al, 2007a, 2008).
The feasibility of obtaining IPD from prognostic studies has
recently been considered by Altman et al (2006), and more
generally for survival studies by Ioannidis et al (2002). Altman et al
concluded that the IPD approach is possible, although it can be
a ‘long, expensive, and rather laborious process’. To reduce the
time and cost required, one option is to seek IPD from only a ‘well-
defined list’ of studies, as successfully done by Look et al (2002) in
breast cancer, although this approach may be criticised for
potentially subjective decisions regarding what constitutes a
‘well-defined list’ and a ‘large’ or ‘high-quality’ study.
TOWARDS MULTI-CENTRE AND COLLABORATIVE
RESEARCH
Prospectively planned pooled analyses
It is clear that collaboration across multiple disciplines and
multiple centres is required to achieve the necessary progress
outlined in the sections ‘Primary studies of progostic markers’ and
‘Systematic reviews and meta-analysis’. However, such a colla-
borative drive naturally points away from the retrospective pooling
of data, and points toward prospectively planned pooled analyses
and prospective multi-centre studies. Indeed, McShane et al
(2005a) state that ‘More importantly, the necessity of large,
definitive prospective studies or prospectively planned meta-
analyses for tumour marker research must be recognised.’ Research
groups working together and communicating from the outset of
their studies – as protocols and clinical objectives are being
formulated – are the best way to achieve consistency in, for example,
study design, markers assessed, method of measurement, treatments
considered, outcomes of importance, and statistical analysis. A
pooled analysis could then be planned prospectively to answer pre-
specified clinical questions, with investigators committing in
advance to the availability of their IPD at the end of their study.
Prospective multi-centre studies are the ideal, but may be time-
consuming and costly. For prognostic markers measurable on
stored material, a helpful compromise could be a protocol-based
pre-planned pooled analysis of retrospective data from several
centres. Such a project would start with a detailed protocol
specifying inclusion and exclusion criteria for patients and
treatments allowed. The availability of complete data for some
‘basic’ variables and a minimum amount of follow-up could be
inclusion criteria. Compared with the effect of markers, the effect
of most treatments is often relatively small. Therefore, the
variation of treatment across several centres will not matter too
much. The situation is more complicated if the treatment effect
depends strongly on the marker (treatment–covariate interaction).
However, that is rare. Such a situation requires a more thoughtful
analysis, for example, a stratified analysis or separate subgroup
investigations. Ideally, in all centres, the same method of the
marker measurement has to be used, otherwise methods to
transfer data to one scale are required, and other technical
variations across studies are restricted as far as possible.
Combining the estimated effects from the individual centres
(studies) using meta-analysis methodology or by stratifying the
analysis by centre (or treatment) gives the flavour of a pre-planned
meta-analysis, a design used for some time in epidemiology
(Blettner et al, 1999; Boffetta et al, 2004; Cardis et al, 2005). A
combined analysis of data from several centres (studies), which is
based on a detailed protocol before data collection is started, is an
important design for future prognostic marker research. The
required sample size can be reached by adding more centres, and
the time frame for such a study can be ‘relatively’ short as data
from patients with long-term follow-up can be used. As thousands
of patients are required for a reliable assessment of the importance
• Use, as far as possible, consistent inclusion and exclusion criteria across studies, 
and if appropriate re-instate patients into the analysis who were originally excluded.
• Use up-to-date follow-up information, which is potentially longer than that used in 
the study publication.
• Obtain estimates for those missing or poorly reported outcomes and summary 
statistics across studies; it may thus reduce the problem of selective within-study 
reporting.
• Obtain more direct estimates (e.g., of the hazard ratio) where earlier only 
indirect estimates were available. 
• As far as possible, standardise the strategy of statistical analysis across studies 
• Produce adjusted estimates where earlier only unadjusted estimates were 
available.
• Use a (small) consistent set of adjustment factors across studies.
• Use a consistent cutpoint across studies, or produce continuous marker results.  
• Assess the benefits of using combinations of markers.
• Assess specific subgroups of patients across studies (e.g., pre-menopausal, stage 4 
disease), and assess whether patient level characteristics (such as, age and treatment) 
are effect modifiers across studies.
• Identify those studies that contain the same or overlapping sets of patients.
• Assess model assumptions in each study, such as proportional hazards.
• Produce appropriate statistical validation of the models developed.
Figure 6 Summary of the potential benefits of having individual patient data (IPD) for a meta-analysis of prognostic marker studies.
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cooperate in such a project. Such an approach has many scientific
advantages to a situation where large (and small) centres conduct
studies on their own with hundreds of patients, but with variations
in inclusion criteria, such as measurement techniques, analysis
strategies, and so on. As obvious from the past, such unstructured
type of research will not lead to scientific answers urgently needed.
McShane et al (2005a) suggest ‘cultural changes will be required’,
and the necessity of this type of collaboration has been recognised
before by clinical trialists and by the epidemiologic community.
Tissue banks
Another promising possibility is the use of samples from a tissue
bank, especially one that is established to facilitate prognostic
research (Burke and Henson, 1998; Schilsky et al, 2002). Tumour
samples and corresponding data may come from patients treated
within a prospective (randomised) trial, or they may come from
those not taking part in a trial. In the earlier case, storing may be
connected with a more specific project for a specified population;
in the latter case, patients may belong to a very heterogeneous
population with regard to characteristics, treatment, and follow-
up. Studies using the resource of a tissue bank would benefit from
standardised collection and storage of samples, as well as from
good quality baseline and follow-up data. If new assays need to be
performed, they can be carried out using standardised laboratory
methods. After the first few years, studies using such samples
would have access to adequate clinical follow-up, and so could be
carried out quickly but without the disadvantages associated with
retrospective studies.
Hayes et al (2008) concur that the exciting potential of prog-
nostic markers highlights the ‘importance of prospective collec-
tion, processing, and storage of biospecimens’ to help identify
markers that facilitate individualised treatment strategies. A highly
commendable example of such an initiative is in the bladder
cancer field, where Goebell et al (2004) are establishing a multi-
institutional bladder cancer database and a virtual tumour bank as
a resource for participating institutions to evaluate the biological
and prognostic significance of potential markers. More generally,
the Confederation of Cancer Biobanks (CCB) are developing
biobank resources for cancer research and promoting consistency
in how tissue samples are prepared and preserved, thus to facilitate
research investigations involving a larger number of patient
samples. Arguments against tissue banks usually relate to
confidentiality or to medico-legal concerns, but increasingly tissue
banks are accompanied by strong legal and ethical requirements,
and require patient consent. A discussion of the current ethical
issues involving tissue banks is reported by Ravid (2008).
Future single and multi-centre prospective prognostic marker
studies can also facilitate the initiation of tissue banks by providing
their patient tissue samples and archiving their IPD of each patient’s
baseline covariates, clinical follow-up, and eventual outcomes. This
would allow further investigations in the light of new information
after the studies ended; for example, if subsequently a new marker is
discovered, then the tissue samples could be assessed for this
marker and comparison made to the existing markers. Data from
such a marker can be most relevant to the investigations of
treatment–covariate interactions in a (single) large randomised
trial, but it can also be used in prospectively planned pooled
analyses as noted above. For a recent example investigating several
markers for an interaction with treatment in a lung cancer trial, see
Olaussen et al (2006) and Filipits et al (2007a,b).
DISCUSSION
Any insight into the future health of an individual patient is
advantageous, and so prognostic markers can potentially play a
vital part in clinical decision-making (Windeler, 2000). It is
imperative, therefore, that researchers produce reliable and
informative evidence regarding the prognostic markers available
for practice. However, for whatever reason, it is clear that
prognostic marker studies have been neglected in the drive to
improve medical research. The responsibility for this lies with all
1. A new primary study 
Initiation should be based on 
information from earlier
exploratory studies, systematic 
reviews, or meta-analyses. 
Investigators should seek to 
achieve: 
- pre-registration of study where 
possible;
- a clear and transparent protocol 
with pre-specified hypotheses and 
objectives;
- proper study design, preferably 
prospective if a phase III study;
- adequate sample size;
- appropriate statistical analysis 
and clear reporting of all 
outcomes and markers assessed;
- adjustment for other established 
and important traditional markers;
- clear description of the 
limitations and clinical 
implications of the study;
- availability of their individual 
patient data for subsequent meta-
analysis.
2. Systematic review and 
meta-analysis using 
individual patient data 
Investigators should seek to achieve: 
- a clear and transparent protocol with 
pre-specified hypotheses and 
objectives; 
- clear reporting of the search strategy 
used to identify relevant studies; 
- an assessment and report of the 
quality of each study; 
- IPD from a clearly defined set of 
studies, such as those with highest
quality or largest patients;
- appropriate meta-analysis and clear 
reporting of results, with an 
investigation of any potential 
publication bias concerns;
- adjustment for other established and 
important traditional markers; 
possible assessment of 
combinations of markers; 
- clear description of any study 
limitations, and implications for 
clinical practice and future research.
3. Prospectively planned 
Pooled analysis of
Individual patient data 
Investigators should seek to achieve 
- a clear and transparent protocol with 
prespecified hypotheses and objectives;
- collaboration of multiple research 
groups to produce methodological 
consistency between studies, e.g., in 
the markers assessed and their method 
of measurement;
- studies using retrospective patient 
data require detailed decisions about 
inclusion/exclusion criteria and 
completeness of ‘basic factors’;
- appropriate meta-analysis and clear 
reporting of results, including all 
markers and outcomes assessed;
- adjustment for other established and 
important traditional markers; possible 
assessment of combinations of 
markers;
- clear description of any study 
limitations, and implications for 
clinical practice and future research.
4. Patient samples stored in 
a tumour bank alongside 
detailed individual patient 
data regarding long, high-
quality clinical follow-up 
Investigators should collaborate across 
multiple research groups to initiate a 
tumour bank. This can then be supported 
by: 
- providing tumour samples to the tumour 
bank for each of the patients in their 
study, which should preferably be 
prospective and performed in 
conjunction with other studies to achieve 
methodological consistency;
- providing supplementary patient data 
with detailed baseline information, the 
high-quality clinical follow-up, and 
eventual patient outcomes. Such 
information should be regularly updated;
- allowing tumour samples to be accessed 
to facilitate high-quality studies 
assessing the potential of new markers 
or new assays in relation to existing 
markers or assays used in practice.  
Evidence-base 
Figure 7 Pathways to high-quality evidence regarding the prognostic ability of a marker, following publication of initial hypothesis generating studies.
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measuring markers in the laboratory, to those designing and
implementing primary studies, to those analysing and reporting
results, and to those reviewing and publishing studies. We must
now work together across multiple disciplines, and move towards
transparent, high-quality, clinically relevant research relating to
prognostic markers. Higher-quality prognostic marker research is
desperately needed and is attainable. To achieve such progress,
collaborative and multi-disciplinary teams should be an essential
part of future prognostic studies, including clinicians, biologists,
and statisticians, among others. Research on treatment strategies
has successfully involved international and multi-disciplinary
collaborations for many years, and this is undoubtedly the way
forward for prognostic marker research. Indeed, the best chance
of answering important questions about prognosis is likely to
come from ‘a systematic, sustained programme of epidemio-
logic research, coordinated among cognate research groups’
(Hemingway, 2006). To this end, we encourage researchers to
join the newly registered Prognosis Methods Group within the
Cochrane Collaboration (Riley et al, 2007b).
In this paper, we have encouraged progress towards higher-
quality prognostic studies by explaining where current deficiencies
lie, and by discussing some existing guidelines regarding the
design, clinical relevance, analysis, and reporting of such studies.
Hemingway (2007) recommends that: ‘We need not only to
develop quality standards of primary, secondary, and tertiary
prognosis research but also to secure their implementation’.
Cultural changes thus need to be embedded in the research
community, with continued dissemination of best practice made
within and across research groups, and at national and interna-
tional meetings. A pivotal role in ensuring good practice is held by
the editors of and reviewers for clinical journals, who can enforce
certain standards. For example, some journals require the pros-
pective registration of randomised controlled trials (De Angelis
et al, 2004), and this is an option worth exploring further for
prognostic studies. Researchers also need to look beyond single
prognostic studies and consider the bigger picture: the clinical
utility of a marker will only be established through multiple
high-quality studies conducted over a period of time. Prospective
phase III studies, prospectively planned meta-analyses of pro-
spective or retrospective data, the availability of IPD, and the
initiation of tumour banks all support the evolution of prognostic
marker evidence. In Figure 7 we summarise this process and
indicate the different stages in which researchers can make a
significant contribution to a marker’s evidence-base. Research
groups should strive for such opportunities, and make a long-
standing commitment towards high-quality and collaborative
studies in the future. Only then will we achieve the evidence-
based use of markers in practice and ensure the most appropriate
patient care, which should be the aim of all of us.
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